<i>NRG1</i> fusion-positive solid tumors: clinical detection, genomic landscape, and real-world data in pancreatic cancer
NRG1 fusions are a newly described clinically actionable target in solid tumors. We report the landscape of NRG1+ cancers and highlight the importance of RNA testing. NRG1+ PDAC is enriched in younger patients with KRAS wild-type disease and has a unique biology.
Authors
- GC Kahn
- Marc Ladanyi
- Purvil Sukhadia (ORCID: https://orcid.org/0000-0002-6079-0871)
- Sara DiNapoli (ORCID: https://orcid.org/0009-0005-4099-1034)
- Zeynep Tarcan (ORCID: https://orcid.org/0000-0002-5046-7536)
- Kerem Özcan (ORCID: https://orcid.org/0000-0003-4267-4794)
- Mary Troxel (ORCID: https://orcid.org/0000-0003-2201-473X)
- Richard Kinh Gian (ORCID: https://orcid.org/0000-0002-6554-0310)
- Alexander Edward Dela Cruz Drilon (ORCID: https://orcid.org/0000-0001-6806-9061)
- Matteo Repetto
- James J. Harding (ORCID: https://orcid.org/0000-0002-7029-4310)
- Eileen Mary O'Reilly (ORCID: https://orcid.org/0000-0002-8076-9199)
- Rogelio Velasco (ORCID: https://orcid.org/0000-0003-0627-9623)
- Olca Baştürk (ORCID: https://orcid.org/0000-0003-2747-1366)
- Alison M. Schram (ORCID: https://orcid.org/0000-0002-6070-2413)
- Soo-Ryum Yang
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Lung Center of the Philippines (PH)
- Hunter College (US)
- Philippine Heart Center (PH)
Publication Details
- Journal
- JNCI Journal of the National Cancer Institute
- Published
- 2025-12-06
- DOI
- https://doi.org/10.1093/jnci/djaf361
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00